In addition, a recently study reported stress hormone activation of β2-AR promotes EGFR TKI resistance in cell lines and in mouse models of EGFR mutant NSCLC and that this can be blocked by anti-IL-6 antibodies or β-blockers (33). The gene discussed is ADRB2; the disease is non-small cell lung carcinoma.